Figure 7
From: Gene Expression and Methylation Analyses Suggest DCTD as a Prognostic Factor in Malignant Glioma
The hypothesis about recommission of gemcitabine as an adjuvant therapy for malignant glioma. The strong proliferation of tumor cells requires active synthesis of genetic material. In the process of genetic material synthesis, the protein product of DCTD, dCMP deaminase, plays an important catalyzing role. The ready-made inhibitor of DCTD, gemcitabine, could suppress the synthesis of dTMP and cause a shortage of genetic material, leading to inhibition of the hyperactive proliferation of tumor cells.
